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Abstract
Background: AKT signaling promotes cell growth, proliferation and survival and is hyperactivated
in many cancers. TOR complex 2 (TORC2) activates AKT by phosphorylating it on the
'hydrophobic motif' site. Hydrophobic motif site phosphorylation is needed only for a subset of
AKT functions. Whether proliferation of tumor cells depends on TORC2 activity has not been
thoroughly explored.
Methods: We used RNAi-mediated knockdown of rictor to inhibit TORC2 activity in MCF7 and
PC3 tumor cells to analyze the importance of TORC2 on proliferation of tumor cells.
Results: TORC2 inhibition reduced proliferation and anchorage-independent growth of both cell
lines. Rictor depleted cells accumulated G1 phase, and showed prominent downregulation of Cyclin
D1.
Conclusion: This study provides further evidence that inhibition of TORC2 activity might be a
useful strategy to inhibit proliferation of tumor cells and subsequent tumor growth.
Background
AKT signaling promotes cell growth, proliferation and sur-
vival and is hyperactivated in numerous cancers
(Reviewed in [1,2]). AKT kinase activity is principally
determined by the level of phosphatidylinositol-3,4,5-tri-
phosphate (PIP3) in the plasma membrane of cells, which
is generated by phosphatidylinositol-3-kinase (PI3K)
upon stimulation of receptor tyrosine kinases. PI3K is
counteracted by the lipid-phosphatase and tumor sup-
pressor PTEN, which converts PIP3 back to PIP2
(Reviewed in [1,2]). When PIP3 levels are elevated, AKT is
recruited to the plasma membrane and phosphorylated in
the activation loop by PDK1. In addition, AKT contains a
highly conserved C-terminal hydrophobic motif (HM)
that must also be phosphorylated for full AKT activation
in vitro [3].
Recent studies in mammals and Drosophila have demon-
strated that TORC2 is responsible for HM site phosphor-
ylation [4-6]. Surprisingly, TORC2-mediated
phosphorylation only affects a subset of AKT functions.
MEFs lacking essential TORC2 components show reduced
phosphorylation of FOXO, but not reduced phosphoryla-
tion of TSC2 or GSK-3, although all three are well-estab-
lished AKT targets [7,8]. In Drosophila, TORC2 loss-of-
function phenotypes are substantially different from
those of the other AKT pathway members [6]. While Dro-
sophila AKT and its upstream regulators, such as PI3K and
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PDK1, are essential for viability and cell growth, flies lack-
ing TORC2 are viable and display only minor growth
impairment under standard growth conditions. However,
TORC2 is required for tissue overgrowth upon hyperacti-
vation of AKT signaling, e.g. in the case of PTEN loss-of-
function. This suggests that TORC2 inhibitors might be a
useful for treating cancers that depend of high AKT signal-
ing. Since TORC2-mediated phosphorylation is essential
for only a subset of AKT functions, it is possible that tar-
geting TORC2, instead of other AKT pathway members,
would minimize unwanted consequences resulting from
more general inhibition of AKT activities.
In order to evaluate the potential of TORC2 inhibition in
cancer treatment, it is important to analyze which AKT
functions depend on TORC2 in malignant cells. Here we
have analyzed the effects of TORC2 inhibition on prolif-
eration and anchorage independent growth in two differ-
ent tumor cells, MCF7 breast cancer and PC3 prostate
cancer cells. Inhibition of TORC2 activity by knockdown
of an essential component, Rictor, inhibited cell cycle pro-
gression, cell proliferation and anchorage-independent
growth in both cell types. Our results suggest that inhibi-
tion of TORC2 activity might be a useful strategy to inhibit
proliferation of tumor cells and subsequent tumor
growth.
Methods
Cell culture and treatments
MCF7 and PC3 cells were maintained in DMEM with 10%
FCS and penicillin/streptomycin in humidified 5% CO2
atmosphere at 37°C. The siRNAs targeting human rictor
were Hs_AVO3_1 (target sequence: AAACAAGGCTGT-
GATTCTA) and Hs_AVO3_2 (target sequence: AAAGAC-
TACAGCAACAAAGAA; Qiagen). The negative control
(non-silencing) siRNA had target sequence AATTCTC-
CGAACGTGTCACGT. siRNAs were transfected by using
HiPerFect reagent (Qiagen) according to manufacturer's
protocol. For AKT kinase assays, cells were treated with
Insulin (Sigma, 10 μg/ml) and wortmannin (Sigma, 50
nM) for 20 min.
Western blotting and AKT kinase assay
After treatments cells were washed once with cold PBS and
lysed by boiling in Laemmli sample buffer, resolved on
SDS-PAGE, transferred to nitrocellulose membrane and
blotted with the following antibodies: anti-AKT phospho-
S473, anti-AKT, anti-Cyclin D1 (Cell Signaling Technol-
ogy), anti-Rictor (Bethyl Laboratories), anti-GAPDH
(Santa Cruz Biotechnology). AKT kinase assay was pur-
chased from Cell Signaling Technology and used accord-
ing to the manufacturer's protocol. The intensities of the
phospho-GSK3 bands were quantified by using the
ImageJ software (NIH #3877). The total levels of GSK-3
crosstide fusion protein were visualized by Coomassie
staining.
Proliferation and cell death assays
Cells were plated at low density, transfected with siRNAs
and allowed to proliferate for 2 days. After that, cells were
trypsinized, diluted, plated, re-transfected, and allowed to
proliferate another four days. Cells were counted with a
counting chamber. For analyzing the amount of cell
death, cells were seeded on chambered slides and trans-
fected with the siRNAs for 4 days. Cells were fixed with 4%
paraformaldehyde and nuclei were stained with DAPI.
Cells were imaged by confocal microscopy and condensed
nuclei were calculated. Cell death and nuclear condensa-
tion in MCF7 cells was induced by staurosporin treatment
(1 μM/3 h).
Soft agar assay
0.5% agar (1.5 ml/35 mm plate) containing DMEM, 10%
FCS, and penicillin/streptomycin was used as base agar.
Two days after siRNA transfection, 5000 cells were seeded
into 1.5 ml of 0,35% medium-containing agar that was
plated on top of the base agar. The plates were incubated
in humidified 5% CO2 atmosphere at 37°C for 21 days,
stained with 0.5 ml of 0.005% Crystal Violet for 1 h and
counted using a microscope.
Cell cycle analysis
Three days after transfection cells were collected, washed
by PBS and fixed with 70% ethanol on ice for 1 h. Fixed
cells were stained with propidium iodine (20 μg/ml) in
the presence of RNAse A (200 μg/ml) in PBS with 0.1%
Triton X-100 for 15 min in 37°C. Stained cells were ana-
lyzed by flow cytometry.
Results
Rictor depletion inhibits AKT phosphorylation and activity 
in MCF7 and PC3 tumor cells
In order to analyze the importance of TOR complex 2 for
growth of tumor cells, we sought to prevent its activity by
downregulating Rictor, an essential component of TORC2
[9,10]. We used two independent siRNAs directed against
rictor mRNA and, as a control, an siRNA not targeting any
human proteins. Both rictor siRNAs efficiently lowered
Rictor protein levels in MCF7 and PC3 cells, compared to
cells transfected with control siRNA (Fig. 1A).
TORC2 phosphorylates AKT on the hydrophobic motif
site, which led us to analyze the effect of Rictor knock-
down on this phosphorylation event. Immunoblot analy-
sis showed that Rictor depletion led to strong inhibition
of AKT hydrophobic motif phosphorylation in both cell
lines, whereas total levels of AKT remained unaltered (Fig.
1A). To directly analyze the effect of Rictor depletion on
AKT kinase activity, we performed a kinase assay, byBMC Cancer 2008, 8:282 http://www.biomedcentral.com/1471-2407/8/282
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immunoprecipitating AKT and assaying its ability to phos-
phorylate in vitro a protein containing a GSK-3 peptide
harboring a consensus phosphorylation site for AKT. As
expected, AKT kinase activity was induced when cells were
treated with insulin and inhibited by PI3K inhibitor wort-
mannin (Fig. 1B). In line with the strongly reduced AKT
hydrophobic motif phosphorylation, the insulin-induced
AKT kinase activity was reduced to ~20% in both cell lines
upon Rictor depletion (Fig. 1B).
Inhibition of tumor cell proliferation and anchorage 
independent growth upon Rictor depletion
As an initial assessment for the effects of TORC2 inhibi-
tion, we analyzed the amount of cell death and the rate of
proliferation of MCF7 and PC3 cells upon Rictor deple-
tion. Controlled amounts of siRNA-transfected cells were
plated at low density and allowed to proliferate for several
days. During the growth period, rictor siRNAs did not
cause significant increase in cell death, observed either by
the extent of cell detachment (data not shown) or by ana-
lyzing nuclear morphology (Fig. 2A). Intriguingly, cell
counts indicated that Rictor depletion strongly inhibited
proliferation of MCF7 cells (Fig. 2B). Proliferation of PC3
cells was also significantly inhibited, albeit less strongly
than in the case of MCF7 cells (Fig. 2B).
Anchorage-independent growth is a hallmark of trans-
formed cells that correlates well with their ability to be
invasive and metastatic. AKT activity is crucial for tumor
growth, not only because it promotes proliferation, but
because it allows anchorage-independent growth by pre-
venting detachment-induced apoptosis, anoikis [11].
Therefore, we performed a more stringent test to evaluate
the importance of TORC2 in respect to tumor cell growth
by analyzing the anchorage-independent growth of the
MCF7 and PC3 cells after Rictor depletion. The control
siRNA-treated cells formed colonies in soft agar (Fig. 3A,
B), but transfection of rictor siRNA almost totally abol-
ished the formation of colonies, demonstrating that
TORC2 activity is required for anchorage-independent
growth of MCF7 and PC3 cells (Fig. 3A, B).
Accumulation of cells in G1 phase and downregulation of 
Cyclin D1 upon rictor knockdown
Previous work has shown that AKT activity is needed for
G1/S progression during the cell cycle, which can be
Rictor depletion reduces AKT HM phosphorylation and inhibits AKT kinase activity Figure 1
Rictor depletion reduces AKT HM phosphorylation and inhibits AKT kinase activity. (A) MCF7 and PC3 cells were 
treated for five days with two independent siRNAs against rictor or with a control siRNA not targeting any human protein. 
Cells were lysed by boiling in sample buffer and proteins resolved by SDS-PAGE. Levels of Rictor expression and AKT phos-
phorylation and expression were analyzed by immunoblotting with anti-Rictor, anti-AKT and antibody specific for the phos-
phorylated form of the HM site, P-S473. (B) Cells were treated for five days with rictor siRNA, treated with insulin (Ins) or 
wortmannin (W) or left untreated (C). Cells were lysed and AKT was immunopurified with immobilized AKT antibodies. To 
measure AKT kinase activity, the immunoprecipitates were incubated with paramyosin-fused GSK-3 crosstide in the presence 
of ATP. The level of phosphorylation was analyzed by blotting with antibodies specific to phospho-GSK-3. Total GSK-3 level is 
shown as a loading control.BMC Cancer 2008, 8:282 http://www.biomedcentral.com/1471-2407/8/282
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explained, at least partially, by regulation of Cyclin D1
levels [12], reviewed in [13]. To examine whether the
reduced rate of proliferation upon TORC2 inhibition
might be explained by inhibition of cell cycle progression,
we analyzed the effects of Rictor depletion on the cell
cycle profile. Both MCF7 and PC3 cells displayed a clear
enrichment of cells in G1 when treated with the siRNAs
against Rictor (Figure 4A). MCF7 cells showed a shift from
Inhibition of TORC2 reduces proliferation of MCF7 and PC3 cells Figure 2 (see previous page)
Inhibition of TORC2 reduces proliferation of MCF7 and PC3 cells. (A) The amount of programmed cell death (PCD) 
was analyzed by calculating the percentage of cells displaying nuclear condensation 4 days after siRNA treatments. In the table 
the percentage of condensed nuclei and the number of cells analyzed is displayed. Note that MCF7 cells lack functional caspase-
3, which makes them resistant and affects their mode of cell death [20]. When treated with the commonly used cell death 
inducer, staurosporin, MCF7 cells undergo nuclear condensation without the nuclear fragmentation typical of normal apoptotic 
cells (upper panel). (B) MCF7 and PC3 cells were plated at low density and transfected with two independent rictor siRNAs or 
with a control siRNA. Cells were allowed to proliferate for two days until they reached near confluency, they were trypsinized, 
diluted and replated at low density and retransfected with the siRNAs. Cells were allowed to proliferate another four days 
until the control cells were nearly confluent. Cells were trypsinized, resuspended and counted with a counting chamber. All 
samples were done in three replicates. * Students t-test p < 0.01.
Inhibition of anchorage independent growth upon Rictor depletion Figure 3
Inhibition of anchorage independent growth upon Rictor depletion. (A) MCF7 and PC3 cells were transfected with 
the siRNAs. Two days after transfection cells were detached with trypsin and seeded into soft agar. Colonies were allowed to 
grow for three weeks after which they were stained with crystal violet. (B) The number of visible colonies in a defined area was 
counted in three replicate samples. * Student's t-test p < 0.01.BMC Cancer 2008, 8:282 http://www.biomedcentral.com/1471-2407/8/282
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Accumulation of cells in G1 phase upon rictor depletion correlates with downregulation of Cyclin D1 Figure 4
Accumulation of cells in G1 phase upon rictor depletion correlates with downregulation of Cyclin D1. (A) Flow 
cytometry histograms showing accumulation of cells in G1 phase after depletion of rictor. Cells were treated with siRNAs for 
five days, fixed with ethanol, stained with propidium iodine. DNA content was analyzed by flow cytometry. M1: G1, M2: S, M3: 
G2/M phase. (B) Cells were treated with control or rictor siRNAs for five days. Cyclin D1 levels were analyzed by immunob-
lotting with anti-CyclinD1. GAPDH was used as loading control.BMC Cancer 2008, 8:282 http://www.biomedcentral.com/1471-2407/8/282
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~60% to > 90% of cells in G1. The effect was similar, but
less pronounced in PC3 cells. We next analyzed Cyclin D1
levels by immunoblotting after Rictor depletion. Rictor
depletion strongly reduced the expression of Cyclin D1
(Figure 4B), suggesting that phosphorylation of the
hydrophobic motif of AKT is needed to maintain Cyclin
D1 expression and subsequent cell cycle progression.
Discussion and conclusion
In order to evaluate the potential of TORC2 inhibition as
a strategy to impair tumor cell proliferation, we have ana-
lyzed the consequences of Rictor depletion in two distinct
tumor cell lines MCF7 and PC3. Inhibition of TORC2
activity prevented proliferation and anchorage independ-
ent growth of both MCF7 and PC3 cells, although MCF7
were more sensitive to reduced TORC2 activity. Analysis
of cell cycle profiles revealed a clear enrichment of cells in
G1 phase in TORC2-inhibited cells, which coincided with
a strong downregulation of Cyclin D1. These findings sug-
gest that loss of HM site phosphorylation may be suffi-
cient to mimic the effects of a more global inhibition of
AKT activity in this context, although we cannot rule out
the possibility of AKT-independent effects. In sum, our
study shows that proliferation and anchorage-independ-
ent growth of tumor cells can be efficiently prevented by
inhibiting TORC2, which therefore could be an effective
strategy for treatment of cancers that depend on high AKT
activity.
Which AKT functions are dependent on TORC2-mediated
HM phosphorylation? Several studies provide evidence
that two downstream effectors of AKT, FOXO1/3a and
TORC1, respond differently to loss of AKT HM phospho-
rylation. In both Drosophila and mammalian systems,
loss of TORC2 activity reduces phosphorylation-mediated
inhibition of FOXO, whereas TORC1 activity is unaffected
by loss of AKT HM phosphorylation [4,6-8]. This differ-
ence is reflected in the Drosophila TORC2 loss-of-func-
tion phenotypes. While loss of AKT, Rheb or TOR cause a
clear reduction of cell size [14-16], inhibition of TORC2,
and consequently AKT HM phosphorylation, does not
(VH & SC, unpublished observation). FOXO1/3a, on the
other hand, has been shown to be important for regula-
tion of resistance to oxidative stress and other apoptotic
stimuli, and indeed mammalian cells lacking TORC2 or
AKT HM phosphorylation are hypersensitive to apoptotic
stimuli induced by H2O2 [7], indole-3-carbinol [17] or
etoposide [5]. The effect of TORC2 on cell proliferation
has been studied in fibroblasts derived from knock-out
mouse models of essential TORC2 components Rictor
and Sin1 with controversial results. Shiota and coworkers
analyzed proliferation of Rictor-deficient MEFs and
showed that the cells displayed modestly slower prolifer-
ation compared to wild type [18], whereas Jacinto and
coworkers analyzed sin1-deficient MEFs, and found that
they proliferated similarly to wild type cells [7]. In the two
tumor cell lines analyzed here, acute loss of TORC2 activ-
ity clearly slowed proliferation by slowing or blocking
cells in G1 phase of the cell cycle. Interestingly, a recent
study showed that many gliomas overexpress Rictor and
have elevated TORC2 activity that contributes to their
tumorigenity [19]. Results obtained in our study suggest
that the potential of preventing tumor growth by inhibi-
tion of TORC2 is not only limited to gliomas, but can be
used to inhibit growth of other types of tumors as well.
Sarbassov and coworkers discovered that prolonged treat-
ments with rapamycin or its derivatives can also inhibit
TOR complex 2, in addition to the well-established inhi-
bition of TORC1 [17]. Therefore, rapamycin derivatives
might be useful in preventing growth of tumors depend-
ent on AKT HM phosphorylation. However, strong inhibi-
tion of TORC1 may have undesirable consequences.
Therefore development of small-molecular inhibitors spe-
cific to TORC2 is necessary.
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